Technology evaluation: IMC-1C11, ImClone Systems

Curr Opin Mol Ther. 2001 Aug;3(4):418-24.

Abstract

ImClone is developing IMC-IC11, an anti-angiogenesis chimeric monoclonal antibody specific vascular endothelial growth factor receptor 2 (VEGFR-2, also known Flk-1 in mice), for the potential treatment of cancer [156625]; it in phase I trials for the treatment of colorectal carcinoma [379143]. The related antibody DC-101 provided proof-of-principle that an anti-VEGF receptor antibody could strongly inhibit tumor growth and even cause tumor regression with the glioblastoma tumor cell line, GBM18 [388236]. In May 1998, the company was granted US-05747651 by the USPTO, covering antibodies against the extracellular portion of the FLK-1/KDR receptor [284054].

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Colorectal Neoplasms / therapy*
  • Humans
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptors, Growth Factor / antagonists & inhibitors*
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins / therapeutic use*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Receptors, Growth Factor
  • Recombinant Fusion Proteins
  • Receptor Protein-Tyrosine Kinases
  • Receptors, Vascular Endothelial Growth Factor